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Abstract
This report reviews some of the new studies regarding new hormonal contraceptive formulations
(e.g., Yaz, Qlaira
®, extended-cycle or continuous combined contraceptives, subcutaneous depot
medroxyprogesterone acetate, and ulipristal acetate as an emergency contraceptive). Recent data on
the relationship between hormonal contraceptive use and bone health are also reviewed.
Introduction and context
Hormonal contraception is one of the most widely used
contraceptive modalities and provides very good efficacy
and low failure rates. Continued research has explored
and introduced new formulations and clarified some of
the concerns regarding the use of hormonal contra-
ceptives, and indeed overall reductions in all-cause and
heart disease mortality rates were recently reported by
the UK Royal College of General Practitioners study [1].
This paper reviews some of the important studies on
hormonal contraception reported recently.
Recent advances
Combined hormonal contraceptives
Drospirenone (DRSP) represents the newest generation
of progestogen used in oral contraceptive pills. A large
multicenter prospective observational study [2] assessed
a combined oral contraceptive (COC) containing 30 g
ethinylestradiol (EE) and 3 mg DRSP (Yasmin®; Bayer
AG, Leverkusen, Germany), which improved water
retention symptoms and bleeding pattern. However,
the study is limited by its non-comparative design.
Further comparative studies versus the older COCs are
warranted to provide stronger evidence.
An ultra-low-dose preparation containing 20 g EE and
3 mg DRSP in a novel 24/4 regimen (Yaz; Bayer AG) has
been marketed recently. Its efficacy is similar to, if not
better than, that of older COCs and has an acceptable
bleeding pattern. Yaz is currently the only COC with
reported evidence for and approved indication in
the treatment of emotional and physical symptoms of
premenstrual dysphoric disorder and has shown
improvement in productivity, social activities, and
relationships [3-5].
Another new preparation (Qlaira®; Bayer AG) containing
17-beta-oestradiol instead of EE as the oestrogen
component has been marketed recently. It contains
oestradiol valerate (E2V) and dienogest in a multiphasic
regime that is optimised to provide good efficacy
(adjusted Pearl index of 0.34) and at the same time
satisfactory cycle control [6,7]. It is the first preparation
using natural oestradiol, but clinical benefits over the
older preparations remain to be explored in comparative
studies.
Progestogen-only contraceptives
Depo-subQ provera 104 (Pfizer Inc., NY, USA), a
subcutaneous preparation of depot medroxyprogester-
one acetate (DMPA) 104 mg in 0.65 mL, has been
introduced in recent years. The slightly lower dosage,
optimized for delivery by subcutaneous administration,
was determined in pharmacokinetic studies on both
Caucasian and Asian women to meet the minimum
serum concentration required to provide consistent
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similar to, if not better than, that of the conventional
intramuscular preparation of DMPA (DMPA-IM) and
allows self-administration by the user. A multicenter
clinical study reported no pregnancies out of a total of
16,023 women-cycles. Bleeding disturbances are similar
to DMPA-IM, resulting in discontinuation in 3-4% of
users in 1 year of use, and about 55% of women became
amenorrhoeic with continuing use [8]. A modest weight
gain (of up to 4.5 kg) by 3 years was reported [9].
Emergency contraception
The levonorgestrel (LNG)-only regimen is now a
standard for emergency contraception (EC). The effec-
tiveness of the single-dose regime (LNG 1.5 mg) is
similar to that of split-dose LNG and could minimize
compliance problems and is currently the recommended
regime approved for use up to 72 hours following
unprotected sexual intercourse [10].
Progesterone receptor antagonists/modulators can also be
used for EC. Mifepristone is superior to LNG in efficacy
[10] but is available only in China for EC. Doses of
25-50 mg are very effective, and lower doses (less than
25 mg) may be equally good. Menstrual delay is common
with mifepristone. The progesterone receptor modulator,
ulipristal acetate (CDB-2914), is a new option. Ulipristal
acetate 30 mg (ellaOne; HRA Pharma, Paris, France) has
been recently marketed in Europe as an EC. A meta-
analysis of two randomised controlled trials suggested
that it is more effective than LNG (failure rate 1.4% versus
2.2%), and it can be used up to 5 days after unprotected
sexual intercourse [11].
Hormonal contraceptives and bone health
Multiple reports in the literature have suggested an
association between DMPA use and a decreased bone
mineral density (BMD), which is at least partially
reversible upon discontinuation [12,13], but the clinical
significance has remained unclear, particularly with
regard to the long-term risk of clinical fracture. Recently,
a population-wide case control analysis of contraceptive
use in Danish women who had clinical fractures was
reported; this demonstrated a statistically significant
increase in fracture risk (adjusted odds ratio 1.44, 95%
confidence interval 1.01-2.06) in DMPA-users versus
non-users, with the risk most pronounced in women
more than 50 years old or those who used it for more
than 4 years [14]. However, there were only a small
number of DMPA-users in the cohort, and due to the
nature of the study design, not all potential confounders
might have been addressed. A large-scale randomised
controlled trial sufficiently powered to detect a difference
in fracture risk would be extremely difficult practically.
Further studies in other populations would be warranted
to gather further data. Another multicenter prospective
randomised controlled trial compared subcutaneous
DMPA with the conventional intramuscular DMPA
over a 2-year period and found them to be very similar
in regard to a small reversible BMD loss [15].
On the other hand, it is increasingly recognised that
combined hormonal contraceptives might also have a
potential impact on bone mass accrual in adolescents
and young adults. A systematic review found incon-
sistent data relating to effects of COCs on bone mass in
adolescents and young women, and only one good
quality study was identified; it concluded that COC-users
did not gain as much bone mass as non-users [16].
A 4-year non-randomised follow-up study found a
significantly lower increment in the mean adjusted
bone mineral content in young adolescent (12-19 years
old) usersof combined hormonal contraceptive for more
than 2 years [17]. A population-wide case control
analysis of COC use in Danish women who had clinical
fractures suggested that there is no clear increase in
fracture risk with COCs [18].
Implications for clinical practice
The DRSP-containing combined hormonal contraceptives
offer similar contraceptive efficacy with specific benefits
of improved water retention symptoms and, for Yaz, a
licensed use for treatment of premenstrual dysphoric
disorder. A new COC preparation that contains the
natural 17-beta-oestradiol and that is similar to the
conventional COCs in efficacy and acceptable cycle
control has been marketed; however, its benefits over
the older COCs are yet to be explored and it is markedly
more expensive. A subcutaneous form of DMPA provides
efficacy and side effect profiles that are similar to, if not
more favorable than, those of the conventional intramus-
cular DMPA and provides a self-injectable option.
In regard to EC, the single-dose LNG-only regime is a
recommendedfirst-line option. A new product containing
ulipristal acetate provides a more effective alternative to
LNGandcanbeusedupto5daysafterunprotectedsexual
intercourse. Most reports in the current literature found a
negative effect of both DMPA and combined hormonal
contraceptives on BMD, but the clinical significance
remains debatable. The evidence so far is not adequate
to suggest any limit on their use or any additional
monitoring in users who are otherwise healthy.
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